|
1
|
Sporn MB, Dowsett SA, Mershon J and Bryant
HU: Role of raloxifene in breast cancer prevention in
postmenopausal women: clinical evidence and potential mechanisms of
action. Clin Ther. 26:830–840. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jordan VC and Koerner S: Inhibition of
oestradiol binding to mouse uterine and vaginal oestrogen receptors
by triphenylethylenes. J Endocrinol. 64:193–194. 1975. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Croxtall JD, Emmas C, White JO, Choudhary
Q and Flower RJ: Tamoxifen inhibits growth of oestrogen
receptor-negative A549 cells. Biochem Pharmacol. 47:197–202. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Couldwell WT, Weiss MH, DeGiorgio CM, et
al: Clinical and radiographic response in a minority of patients
with recurrent malignant gliomas treated with high-dose tamoxifen.
Neurosurgery. 32:485–490. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Del Prete SA, Maurer LH, O’Donnell J,
Forcier RJ and LeMarbre P: Combination chemotherapy with cisplatin,
carmustine, dacarbazine and tamoxifen in metastatic melanoma.
Cancer Treat Rep. 68:1403–1405. 1984.PubMed/NCBI
|
|
6
|
Murphy LC and Sutherland RL: Differential
effects of tamoxifen and analogs with nonbasic side chains on cell
proliferation in vitro. Endocrinology. 116:1071–1078. 1985.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Plowman PN: Tamoxifen as adjuvant therapy
in breast cancer. Current status Drugs. 46:819–833. 1993.PubMed/NCBI
|
|
8
|
Mandlekar S and Kong ANT: Mechanisms of
tamoxifen-induced apoptosis. Apoptosis. 6:469–477. 2001. View Article : Google Scholar
|
|
9
|
Carey LA, Dees EC, Sawyer L, et al: The
triple-negative paradox: primary tumor chemosensitivity of breast
cancer subtypes. Clin Cancer Res. 13:2329–2334. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kaplan HG and Malmgren JA: Impact of
triple-negative phenotype on breast cancer prognosis. Breast J.
14:456–463. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Somers-Edgar TJ, Taurin S, Larsen L,
Chandramouli A, Nelson MA and Rosengren RJ: Mechanisms for the
activity of heterocyclic cyclohexanone curcumin derivatives in
estrogen receptor negative human breast cancer cell lines. Invest
New Drugs. 29:87–97. 2011. View Article : Google Scholar
|
|
12
|
Taurin S, Sandbo N, Qin Y, Browning D and
Dulin NO: Phosphorylation of β-catenin by cyclic AMP-dependent
protein kinase. J Biol Chem. 281:9971–9976. 2006.
|
|
13
|
Reagan-Shaw S, Nihal M and Ahmad N: Dose
translation from animal to human studies revisited. FASEB J.
22:659–661. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nielsen TO, Hsu FD, Jensen K, et al:
Immunohistochemical and clinical characterization of the basal-like
subtype of invasive breast carcinoma. Clin Cancer Res.
10:5367–5374. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rush JS, Quinalty LM, Engelman L, Sherry
DM and Ceresa BP: Endosomal accumulation of the activated epidermal
growth factor receptor (EGFR) induces apoptosis. J Biol Chem.
287:712–722. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ueno NT and Zhang D: Targeting EGFR in
triple-negative breast cancer. J Cancer. 2:324–328. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nickerson NK, Mohammad KS, Gilmore JL, et
al: Decreased autocrine EGFR signaling in metastatic breast cancer
cells inhibits tumor growth in bone and mammary fat pad. PLoS One.
7:e302552012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zoncu R, Perera RM, Balkin DM, Pirruccello
M, Toomre D and De Camilli P: A phosphoinositide switch controls
the maturation and signaling properties of APPL endosomes. Cell.
136:1110–1121. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pol A, Lu A, Pons M, Peiró S and Enrich C:
Epidermal growth factor-mediated caveolin recruitment to early
endosomes and MAPK activation. J Biol Chem. 275:30566–30572. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Freedman VH and Shin SI: Cellular
tumorigenicity in nude mice: correlation with cell growth in
semi-solid medium. Cell. 3:355–359. 1974. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Riggs BL and Hartmann LC: Selective
estrogen-receptor modulators - mechanisms of action and application
to clinical practice. N Engl J Med. 348:618–629. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Perry RR, Kang Y and Greaves B: Effects of
tamoxifen on growth and apoptosis of estrogen-dependent and
-independent human breast cancer cells. Ann Surg Oncol. 2:238–245.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gelmann EP: Tamoxifen induction of
apoptosis in estrogen receptor-negative cancers: new tricks for an
old dog? J Natl Cancer Inst. 88:224–226. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kim HT, Kim BC, Kim IY, et al: Raloxifene,
a mixed estrogen agonist/antagonist, induces apoptosis through
cleavage of BAD in TSU-PR1 human cancer cells. J Biol Chem.
277:32510–32515. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Eisen SF and Brown HA: Selective estrogen
receptor (ER) modulators differentially regulate phospholipase D
catalytic activity in ER-negative breast cancer cells. Mol
Pharmacol. 62:911–920. 2002. View Article : Google Scholar
|
|
26
|
Todorova VK, Kaufmann Y, Luo S and
Klimberg VS: Tamoxifen and raloxifene suppress the proliferation of
estrogen receptor-negative cells through inhibition of glutamine
uptake. Cancer Chemother Pharmacol. 67:285–291. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bosch A, Eroles P, Zaragoza R, Vina JR and
Lluch A: Triple-negative breast cancer: molecular features,
pathogenesis, treatment and current lines of research. Cancer Treat
Rev. 36:206–215. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cho EY, Chang MH, Choi YL, et al:
Potential candidate biomarkers for heterogeneity in triple-negative
breast cancer (TNBC). Cancer Chemother Pharmacol. 68:753–761. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hyatt DC and Ceresa BP: Cellular
localization of the activated EGFR determines its effect on cell
growth in MDA-MB-468 cells. Exp Cell Res. 314:3415–3425. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
de Medina P, Payre B, Boubekeur N, et al:
Ligands of the antiestrogen-binding site induce active cell death
and autophagy in human breast cancer cells through the modulation
of cholesterol metabolism. Cell Death Differ. 16:1372–1384.
2009.PubMed/NCBI
|
|
31
|
de Medina P, Paillasse MR, Segala G,
Poirot M and Silvente-Poirot S: Identification and pharmacological
characterization of cholesterol-5,6-epoxide hydrolase as a target
for tamoxifen and AEBS ligands. Proc Natl Acad Sci USA.
107:13520–13525. 2010.PubMed/NCBI
|
|
32
|
Payre B, de Medina P, Boubekeur N, et al:
Microsomal antiestrogen-binding site ligands induce growth control
and differentiation of human breast cancer cells through the
modulation of cholesterol metabolism. Mol Cancer Ther. 7:3707–3718.
2008. View Article : Google Scholar
|
|
33
|
Simonsen A and Tooze SA: Coordination of
membrane events during autophagy by multiple class III PI3-kinase
complexes. J Cell Biol. 186:773–782. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Razi M, Chan EY and Tooze SA: Early
endosomes and endosomal coatomer are required for autophagy. J Cell
Biol. 185:305–321. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sigismund S, Woelk T, Puri C, et al:
Clathrin-independent endocytosis of ubiquitinated cargos. Proc Natl
Acad Sci USA. 102:2760–2765. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Aguilar RC and Wendland B: Endocytosis of
membrane receptors: two pathways are better than one. Proc Natl
Acad Sci USA. 102:2679–2680. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Couet J, Sargiacomo M and Lisanti MP:
Interaction of a receptor tyrosine kinase, EGF-R, with caveolins.
Caveolin binding negatively regulates tyrosine and serine/threonine
kinase activities. J Biol Chem. 272:30429–30438. 1997. View Article : Google Scholar
|
|
38
|
Litwiniuk MM, Roznowski K, Filas V, et al:
Expression of estrogen receptor beta in the breast carcinoma of
BRCA1 mutation carriers. BMC Cancer. 8:1002008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Vladusic EA, Hornby AE, Guerra-Vladusic
FK, Lakins J and Lupu R: Expression and regulation of estrogen
receptor beta in human breast tumors and cell lines. Oncol Rep.
7:157–167. 2000.PubMed/NCBI
|
|
40
|
Kuiper GGJM, Lemmen JG, Carlsson B, et al:
Interaction of estrogenic chemicals and phytoestrogens with
estrogen receptor β. Endocrinology. 139:4252–4263. 1998.
|
|
41
|
Pinton G, Thomas W, Bellini P, et al:
Estrogen receptor β exerts tumor repressive functions in human
malignant pleural mesothelioma via EGFR inactivation and affects
response to gefitinib. PLoS One. 5:e141102010.
|
|
42
|
Lee W-L, Chao H-T, Cheng M-H and Wang P-H:
Rationale for using raloxifene to prevent both osteoporosis and
breast cancer in postmenopausal women. Maturitas. 60:92–107. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wang Z, Zhang X, Shen P, Loggie BW, Chang
Y and Deuel TF: A variant of estrogen receptor-α, hER-α36:
transduction of estrogen- and antiestrogen-dependent
membrane-initiated mitogenic signaling. Proc Natl Acad Sci USA.
103:9063–9068. 2006.
|
|
44
|
Zhang XT, Kang LG, Ding L, Vranic S,
Gatalica Z and Wang ZY: A positive feedback loop of ER-alpha36/EGFR
promotes malignant growth of ER-negative breast cancer cells.
Oncogene. 30:770–780. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Lin SL, Yan LY, Zhang XT, et al:
ER-alpha36, a variant of ER-alpha, promotes tamoxifen agonist
action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt
pathways. PLoS One. 5:e90132010. View Article : Google Scholar
|
|
46
|
Nguyen DX, Bos PD and Massague J:
Metastasis: from dissemination to organ-specific colonization. Nat
Rev Cancer. 9:274–284. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Viale G, Rotmensz N, Maisonneuve P, et al:
Invasive ductal carcinoma of the breast with the ‘triple-negative’
phenotype: prognostic implications of EGFR immunoreactivity. Breast
Cancer Res Treat. 116:317–328. 2009.
|
